December 8, 2025Blood

Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major

View Full Paper

Ask AI

Bookmark

Authors

QHQiulin HuangFirst Affiliated Hospital of University of South China

Discussion

Member takes

Implication

Pharmacodynamic effects increased ATP production and reduced oxidative stress in erythroid cells from β-thalassemia major, suggesting therapeutic potential for Snh-119014.

Key Points

Snh-119014 increased ATP production by up to 129% in RBCs from β-thalassemia patients, reducing oxidative stress.
Remarkable decreases in reactive oxygen species (ROS) levels were observed, with a 30.8% reduction from the treatment.
Preclinical assessment involved isolating RBCs and CD34+ cells from β-thalassemia major for metabolic profiling and PK activity evaluation.
These findings indicate potential for Snh-119014 in therapeutic strategies against anemia linked to metabolic stress.

Cite This Study

Qiulin Huang (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236dab5 https://doi.org/10.1182/blood-2025-4698

View Full Paper

Ask AI

Bookmark

Implication

Pharmacodynamic effects increased ATP production and reduced oxidative stress in erythroid cells from β-thalassemia major, suggesting therapeutic potential for Snh-119014.

Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major

Discussion

Member takes

Implication

Key Points

Cite This Study

Snh-119014, a novel pyruvate kinase activator, enhances ATP production and reduces oxidative stress in erythroid cells from patients with β-thalassemia major

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider